These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 10076573)

  • 1. Enhancement of cisplatin sensitivity in high mobility group 2 cDNA-transfected human lung cancer cells.
    Arioka H; Nishio K; Ishida T; Fukumoto H; Fukuoka K; Nomoto T; Kurokawa H; Yokote H; Abe S; Saijo N
    Jpn J Cancer Res; 1999 Jan; 90(1):108-15. PubMed ID: 10076573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in human non-small cell lung cancer cell lines: relation to DNA damage and repair.
    Bungo M; Fujiwara Y; Kasahara K; Nakagawa K; Ohe Y; Sasaki Y; Irino S; Saijo N
    Cancer Res; 1990 May; 50(9):2549-53. PubMed ID: 2158392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. v-src induces cisplatin resistance by increasing the repair of cisplatin-DNA interstrand cross-links in human gallbladder adenocarcinoma cells.
    Masumoto N; Nakano S; Fujishima H; Kohno K; Niho Y
    Int J Cancer; 1999 Mar; 80(5):731-7. PubMed ID: 10048975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The mechanism of the difference in cellular uptake of platinum derivatives in non-small cell lung cancer cell line (PC-14) and its cisplatin-resistant subline (PC-14/CDDP).
    Ohmori T; Morikage T; Sugimoto Y; Fujiwara Y; Kasahara K; Nishio K; Ohta S; Sasaki Y; Takahashi T; Saijo N
    Jpn J Cancer Res; 1993 Jan; 84(1):83-92. PubMed ID: 8383649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of high mobility group protein binding to cisplatin-damaged DNA.
    Billings PC; Davis RJ; Engelsberg BN; Skov KA; Hughes EN
    Biochem Biophys Res Commun; 1992 Nov; 188(3):1286-94. PubMed ID: 1445361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxicity of cis-[((1R,2R)-1,2-cyclohexanediamine-N,N')bis(myristato)]-platinum (II) suspended in Lipiodol in a newly established cisplatin-resistant rat hepatoma cell line.
    Kishimoto S; Miyazawa K; Terakawa Y; Ashikari H; Ohtani A; Fukushima S; Takeuchi Y
    Jpn J Cancer Res; 2000 Dec; 91(12):1326-32. PubMed ID: 11123433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin.
    Kasahara K; Fujiwara Y; Nishio K; Ohmori T; Sugimoto Y; Komiya K; Matsuda T; Saijo N
    Cancer Res; 1991 Jun; 51(12):3237-42. PubMed ID: 1645616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiation sensitivities in various anticancer-drug-resistant human lung cancer cell lines and mechanism of radiation cross-resistance in a cisplatin-resistant cell line.
    Oshita F; Fujiwara Y; Saijo N
    J Cancer Res Clin Oncol; 1992; 119(1):28-34. PubMed ID: 1400562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of sensitivity to cis-diamminedichloroplatinum (II) by thromboxane A2 receptor antagonists in non-small-cell lung cancer cell lines.
    Kasahara K; Fujimura M; Bando T; Shibata K; Shirasaki H; Matsuda T
    Br J Cancer; 1996 Nov; 74(10):1553-8. PubMed ID: 8932334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ouabain-resistant non-small-cell lung-cancer cell line shows collateral sensitivity to cis-diamminedichloroplatinum(II) (CDDP).
    Ohmori T; Nishio K; Ohta S; Kubota N; Adachi M; Komiya K; Saijo N
    Int J Cancer; 1994 Apr; 57(1):111-6. PubMed ID: 8150528
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular distribution of HMG1, HMG2 and UBF change following treatment with cisplatin.
    Chao JC; Wan XS; Engelsberg BN; Rothblum LI; Billings PC
    Biochim Biophys Acta; 1996 Jun; 1307(2):213-9. PubMed ID: 8679707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of proton pump inhibitor on cell growth and sensitivity to cis-diamminedichloroplatinum(II) in non-small cell lung cancer cell lines.
    Bando T; Kasahara K; Shibata K; Nakatsumi Y; Fujimura M; Matsuda T
    Anticancer Res; 1994; 14(6B):2727-30. PubMed ID: 7872708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines.
    van Moorsel CJ; Pinedo HM; Veerman G; Bergman AM; Kuiper CM; Vermorken JB; van der Vijgh WJ; Peters GJ
    Br J Cancer; 1999 Jun; 80(7):981-90. PubMed ID: 10362105
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of collateral sensitivity to fluorouracil of a cis-diamminedichloroplatinum(II)-resistant human non-small lung cancer cell line.
    Sugimoto Y; Ohe Y; Nishio K; Ohmori T; Morikage T; Fujiwara Y; Saijo N
    Br J Cancer; 1992 Jun; 65(6):857-64. PubMed ID: 1319727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Localization of the binding region of high mobility group protein 2 to cisplatin-damaged DNA.
    Lawrence DL; Engelsberg BN; Farid RS; Hughes EN; Billings PC
    J Biol Chem; 1993 Nov; 268(32):23940-5. PubMed ID: 8226934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modulation of cisplatin sensitivity and accumulation by amphotericin B in cisplatin-resistant human lung cancer cell lines.
    Morikage T; Ohmori T; Nishio K; Fujiwara Y; Takeda Y; Saijo N
    Cancer Res; 1993 Jul; 53(14):3302-7. PubMed ID: 8391922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
    Hospers GA; Mulder NH; de Jong B; de Ley L; Uges DR; Fichtinger-Schepman AM; Scheper RJ; de Vries EG
    Cancer Res; 1988 Dec; 48(23):6803-7. PubMed ID: 2846161
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells.
    Lai SL; Hwang J; Perng RP; Whang-Peng J
    Oncol Res; 1995; 7(1):31-8. PubMed ID: 7549042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alteration of type II regulatory subunit of cAMP-dependent protein kinase in human cisplatin-resistant cells as a basis of collateral sensitivity to 8-chloro-cAMP.
    Nishio K; Morikage T; Kubota N; Ohmori T; Takeda Y; Fujiwara Y; Miki K; Abe K; Saijo N
    Jpn J Cancer Res; 1992 Jul; 83(7):754-60. PubMed ID: 1325432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Resistance of human cervical carcinoma cells to tumor necrosis factor correlates with their increased sensitivity to cisplatin: evidence of a role for DNA repair and epidermal growth factor receptor.
    Nishikawa K; Rosenblum MG; Newman RA; Pandita TK; Hittelman WN; Donato NJ
    Cancer Res; 1992 Sep; 52(17):4758-65. PubMed ID: 1380890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.